There are currently 1519 clinical trials in Baltimore, Maryland looking for participants to engage in research studies. Trials are conducted at various facilities, including Johns Hopkins University, Johns Hopkins Hospital, University of Maryland and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Effects of Simvastatin on Uterine Leiomyoma Size
NCT03400826
Recruiting
The study aims to study the effect of simvastatin on the size of uterine fibroids.
Gender:
FEMALE
Ages:
Between 18 years and 55 years
Trial Updated:
07/09/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Fibroid Uterus, Fibroid Tumor, Leiomyoma, Fibromyoma, Leiomyoma, Uterine
Register for Updates
Skeletal Muscle Energetics and Fatiguability in Older Individuals
NCT04142047
Recruiting
The investigators are studying whether metabolic abnormalities in calf (leg) muscle in older people with and others without HIV are associated with decreased abilities to exercise.
Gender:
ALL
Ages:
Between 60 years and 90 years
Trial Updated:
07/09/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: HIV, HIV Infections
Register for Updates
Physical Activity, Cardiac and Skeletal Muscle Energetics in Healthy Subjects and HFpEF Patients
NCT04998877
Recruiting
This research is being done to better understand the relationship between information collected by wearable devices and clinical measurements in people with heart failure with preserved ejection fraction (HFpEF) and others without HFpEF. This is an observational study with no study intervention or randomization. Participants will undergo baseline history and physical, 12-lead EKG, laboratory studies of blood/serum/urine, echocardiography, activity questionnaire, 6 minute walk test, and placemen... Read More
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
07/09/2025
Locations: Johns Hopkins Hosptial, Baltimore, Maryland
Conditions: Heart Failure With Preserved Ejection Fraction
Register for Updates
ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves
NCT05172973
Recruiting
The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects who are at high or greater risk with a failing aortic bioprosthetic valve.
Gender:
ALL
Ages:
All
Trial Updated:
07/09/2025
Locations: MedStar Union Memorial Hospital, Baltimore, Maryland
Conditions: Aortic Valve Insufficiency, Aortic Valve Stenosis
Register for Updates
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
NCT05270213
Recruiting
RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine production in the tumors. RBS2418 has the potential to be an important therapeutic option for subjects both as monotherapy and in combination with other cancer t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Advanced Cancer
Register for Updates
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698
Recruiting
LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: University of Maryland Baltimore, Baltimore, Maryland
Conditions: Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
Register for Updates
Evaluation of the Electronic Cigarette Withdrawal Syndrome
NCT06066996
Recruiting
The goal of this project is to rigorously evaluate the nature of e-cigarette withdrawal in exclusive e-cigarette users during a monitored abstinence period and the role of nicotine in the expression of this withdrawal syndrome.
Gender:
ALL
Ages:
Between 21 years and 55 years
Trial Updated:
07/09/2025
Locations: Behavioral Pharmacology Research Unit, Baltimore, Maryland
Conditions: E-cigarette Use, Withdrawal
Register for Updates
Delta-8-THC vs. Delta-9-THC on Simulated Driving Performance
NCT06218550
Recruiting
Delta-8-THC is an isomer of delta-9-THC that has become widely available due to the legalization of hemp and its derivatives. Very little controlled research has been conducted with delta-8-THC and some research suggests it produces similar effects to delta-9-THC, albeit at lower potency. The present study will evaluate the dose effects of delta-8-THC, compared with delta-9-THC, on simulated driving performance, field sobriety tests, cognitive performance, and biomarkers of exposure to cannabino... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/09/2025
Locations: Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland
Conditions: Cannabis
Register for Updates
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
NCT06418711
Recruiting
This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/09/2025
Locations: Johns Hopkins University School of Medicine, Baltimore, Maryland
Conditions: MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
Register for Updates
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
NCT06564844
Recruiting
This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Research Site, Baltimore, Maryland +3 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
ALIGN: Aligning Medications With What Matters Most (Demonstration)
NCT06335953
Recruiting
The goal of this clinical trial is to test the effectiveness of a pharmacist-led, primary care-based de-prescribing intervention for people living with dementia (PLWD) and the person's care partners. The intervention consists of the following strategies: 1) a de-prescribing educational brochure designed to activate the patient and care partner; 2) a single telehealth visit in which an embedded clinical pharmacist discusses the benefits and harms of the patient's medications with the patient and... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/08/2025
Locations: Johns Hopkins Community Physicians, Baltimore, Maryland
Conditions: Polypharmacy, Alzheimer's Disease and Related Dementias, Mild Cognitive Impairment
Register for Updates
A Study of Pitolisant in Patients With Prader-Willi Syndrome
NCT06366464
Recruiting
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant in patients living with Prader-Willi syndrome. The primary objective of this study is to evaluate the efficacy of pitolisant in treating excessive daytime sleepiness (EDS) in patients ≥6 years of age with Prader-Willi syndrome. Secondary objectives include assessing the impact of pitolisant on: Irritable and disruptive behaviors Hyperphagia Other... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
07/08/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Prader-Willi Syndrome
Register for Updates